Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.33 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633006 | 0.94 | CYP19A1 (0.37) | CRBNCYP19A1DDB1BRD4TNF | |
| SCHEMBL632788 | 0.91 | CRBN (0.34) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL633378 | 0.89 | SMN1; SMN2 (0.34) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL632635 | 0.87 | ALDH1A1 (0.34) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL632527 | 0.86 | CRBN (0.32) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL633548 | 0.85 | CYP2C19 (0.39) | TNFMAP1LC3B | |
| SCHEMBL633406 | 0.84 | CRBN (0.32) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL3339484 | 0.83 | GAA (0.38) | — | |
| SCHEMBL633625 | 0.83 | ALDH1A1 (0.33) | CRBNDDB1BRD4TNFIL1B | |
| SCHEMBL632755 | 0.82 | CRBN (0.31) | CRBNDDB1BRD4TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093228-B1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2012-02-22 | — | — | EP | disclosed |
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-06-17 | — | — | US | disclosed |
| EP-2093228-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, CYC1 | CRBN 2750/4885CYP19A1 1108/4885DDB1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.